医疗健康 · 生物科技
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
MARKET 市值 5.40B CHF PE 36.4x
Fwd 29.9x 52W 48.22 – 83.25
EODHD · Q 2025-12-31 · 同步 2026-06-02
QUALITY PEG 0.61 营收 YoY 4.7%
▲ ROE 10.4% 营业利润率 26.3% 净利润率 21.4%
ANALYST 股息率 1.24%
⚠ 基本面数据已 42 天未刷新